Compare HDFC Pharma And Healthcare Fund vs SBI Healthcare Opportunities Fund
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 2.1 | 1.93 |
NAV | ₹16.89 | ₹412.51 |
Fund Started | 14 Sep 2023 | 04 Jun 1999 |
Fund Size | ₹1983.91 Cr | ₹3989.42 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹100
₹500
Expense Ratio
2.1
1.93
NAV
₹16.89
₹412.51
Fund Started
14 Sep 2023
04 Jun 1999
Fund Size
₹1983.91 Cr
₹3989.42 Cr
Exit Load
Exit load of 1%, if redeemed within 30 days.
Exit load of 0.50% if redeemed within 15 days
1 Year | 4.61% | -0.86% |
3 Year | - | 22.82% |
5 Year | - | 15.48% |
1 Year
4.61%
-0.86%
3 Year
-
22.82%
5 Year
-
15.48%
Equity | 97.80% | 96.59% |
Cash | 2.20% | 3.34% |
Equity
97.80%
96.59%
Cash
2.20%
3.34%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 10.79% |
Divi's Laboratories Ltd. | 8.35% |
Glenmark Pharmaceuticals Ltd. | 6.45% |
Lupin Ltd. | 6.04% |
Alkem Laboratories Ltd. | 5.78% |
Max Healthcare Institute Ltd. | 5.74% |
Ipca Laboratories Ltd. | 4.56% |
Anthem Biosciences Ltd. | 4.05% |
Torrent Pharmaceuticals Ltd. | 3.89% |
Aster DM Healthcare Ltd. | 3.34% |
Sun Pharmaceutical Industries Ltd. | 11.64% |
Divi's Laboratories Ltd. | 7.05% |
Max Healthcare Institute Ltd. | 5.24% |
Lupin Ltd. | 4.44% |
Laurus Labs Ltd. | 3.89% |
Torrent Pharmaceuticals Ltd. | 3.86% |
Acutaas Chemicals Ltd. | 3.85% |
Cipla Ltd. | 3.79% |
Lonza Group Ag | 3.63% |
Biocon Ltd. | 3.16% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 14 Sep 2023 | 04 Jun 1999 |
Description
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
14 Sep 2023
04 Jun 1999